SYMBICORT SMART: WHAT IS A NEW CLINICAL TRIALS APPROACH?

Abstract

It is estimated that 300 million people suffer from Asthma. The primary goal of national and international asthma management guidelines is to achieve and maintain overall asthma control and to prevent asthma patients from exacerbations. Symbicort SMART is a combination of inhaled corticosteroid – ICS - (budesonide) and long-acting beta(2)-agonist – LABA - (formoterol) which is the only combined asthma medication approved for maintenance and reliever therapy in adult population. Symbicort SMART provides rapid symptom relief and increases asthma control.